Ethnic sensitivity assessment – pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs

Bibliography

• Ministry of Health, Labour and Welfare. Basic principles on global clinical trials. Notification 0928010 (Sep. 28, 2007).
   Google Scholar
• Ando Y, Uyama Y. Multiregional clinical trials: Japanese perspective on drug development strategy and simple size for Japanese subjects. J Biopharm Stat 2012;22:977-87
   PubMed Web of Science ®Google Scholar
• Asano K, Tanaka A, Sato T, Uyama Y. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther 2013;94:195-8
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. Ethnic factors in the acceptability of foreign clinical data E5 (R1). (Feb. 5, 1998)
   Google Scholar
• Zhou H, Tsukamoto Y, Davis HM. Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies? J Clin Pharmacol 2012;52:1273-6
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmcaol Ther 2013;51:187-99
   PubMed Web of Science ®Google Scholar
• Ling J, Lyn S, Xu Z, et al. Lack of racial difference in the pharmacokinetics of subcutaneous Golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol 2010;50:792-802
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Hasunuma T, Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 2011;49:1101-7
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:633-59
   PubMed Web of Science ®Google Scholar
• Module 2.7.2 Summary of Clinical Pharmacology studies in submission dossier of Adalimumab. Pharmaceuticals and Medical Device Agency. 2008. Available from: http://www.info.pmda.go.jp/shinyaku/P200800019/index.html [Last accessed 12 November 2014]
   Google Scholar
• Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011;50:793-807
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watanabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010;184:1968-76
   PubMed Web of Science ®Google Scholar
• Wang W, Lu P, Fang Y, et al. FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011;39:1469-77
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. MAbs 2010;2:256-65
   PubMed Web of Science ®Google Scholar
• Waldmann H. Human monoclonal antibodies: the residual challenge of antibody immunogenicity. Methods Mol Biol 2014;1060:1-8
   PubMedGoogle Scholar
• Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 2006;49:828-36
   PubMed Web of Science ®Google Scholar
• Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol 2014;54:483-94
   PubMed Web of Science ®Google Scholar
• Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009;85:247-58
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96
   PubMed Web of Science ®Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81
   PubMed Web of Science ®Google Scholar